The positive regulatory development follows Gyre’s May 2025 announcement of successful Phase 3 trial results, where Hydronidone met its primary endpoint with 52.85% of treated patients achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback